Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Assessment of myocardial viability in MRI: Comparison of Late Gadolinium Enhancement with Gadovist vs. Magnevist vs. Dotarem
2009-017739-17Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jan 2010
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gadobutrol, gadopentetate dimeglumine and gadoterate meglumine in myocardial infarction (MI) (3 arms), sponsored by Charité – Universitätsmedizin Berlin. Started Jan 2010; status: completed.
02
Drugs
gadobutrolgadopentetate dimegluminegadoterate meglumine
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2009-017739-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017739-17.